Exodus Point Capital Management, LP Geron Corp Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$2.11 - $3.28 $270,995 - $421,263	128,434 New	128,434 $272,000
Q4 2022 Feb 13, 2023	BUY	$2.03 - $2.42 $273,108 - $325,577	134,536 New	134,536 $326,000
Q3 2022 Nov 10, 2022	SELL	$1.67 - $2.94 $60,337 - $106,222	-36,130 Closed	0 $0
Q2 2022 Aug 19, 2022	BUY	$1.19 - $1.65 $42,994 - $59,614	36,130 New	36,130 $56,000
Q1 2022 May 13, 2022	SELL	$0.99 - $1.6 $92,594 - $149,648	-93,530 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$1.22 - $1.72 $3,151 - $4,442	2,583 Added 2.84%	93,530 $114,000
Q3 2021 Nov 15, 2021	BUY	$1.2 - $1.5 $29,900 - $37,375	24,917 Added 37.74%	90,947 $125,000
Q2 2021 Aug 16, 2021	BUY	$1.25 - $1.83 $17,250 - $25,254	13,800 Added 26.42%	66,030 $93,000
Q1 2021 May 17, 2021	BUY	$1.52 - $2.1 $6,536 - $9,030	4,300 Added 8.97%	52,230 $83,000
Q4 2020 Feb 16, 2021	BUY	$1.55 - $2.05 $24,316 - $32,160	15,688 Added 48.66%	47,930 $76,000
Q3 2020 Nov 16, 2020	BUY	$1.59 - $2.19 $51,264 - $70,609	32,242 New	32,242 $56,000

274

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.32B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.